Sanofi has issued a statement clarifying the situation regarding the use of its Plaquenil (hydroxychloroquine) product after it received “very many questions” from French health professionals about whether the product should be given to patients with COVID-19.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?